Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PDE8B | O95263 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282976 | 1.00 | POLB (0.51) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL192841 | 1.00 | POLB (0.51) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL31048468 | 0.98 | POLB (0.50) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL31323435 | 0.98 | POLB (0.50) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL20399730 | 0.98 | POLB (0.50) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL135177 | 0.95 | L3MBTL1 (0.58) | POLBL3MBTL1PDE8BHSD17B10ATM | |
| SCHEMBL133363 | 0.95 | L3MBTL1 (0.58) | POLBL3MBTL1PDE8BHSD17B10ATM | |
| SCHEMBL47049 | 0.95 | L3MBTL1 (0.58) | POLBL3MBTL1PDE8BHSD17B10ATM | |
| SCHEMBL3769601 | 0.91 | HPGD (0.54) | POLBL3MBTL1PDE8BHSD17B10HPGD | |
| SCHEMBL3769598 | 0.91 | HPGD (0.54) | POLBL3MBTL1PDE8BHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731213-A2 | COMBINATION THERAPY INVOLVING MACROCYCLIC INDAZOLE COMPOUNDS | Blossomhill Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4709376-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024263889-A2 | COMBINATION THERAPY INVOLVING MACROCYCLIC INDAZOLE COMPOUNDS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4217361-B1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | GREY WOLF THERAPEUTICS LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-20240383922-A1 | KRAS Modulating Compounds | GILEAD SCIENCES, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| EP-1784182-A1 | 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-16 | — | — | EP | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2007040681-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040682-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
| WO-1991000724-A1 | ALKYNYL AMINES THAT REGULATE CHOLINERGIC NEUROTRANSMISSION | ABBOTT LABORATORIES (US) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | POLB 1188/4885L3MBTL1 3582/4885PDE8B 4853/4885 |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | POLB 1953/4885L3MBTL1 888/4885PDE8B 528/4885 |
| US-20240383922-A1 | KRAS Modulating Compounds | KRAS, NRAS, HRAS | POLB 1907/4885L3MBTL1 2862/4885PDE8B 2214/4885 |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | POLB 2277/4885L3MBTL1 1534/4885PDE8B 2500/4885 |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | POLB 2277/4885L3MBTL1 1534/4885PDE8B 2500/4885 |
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | HBZ, HBB, HBG2 | POLB 4442/4885L3MBTL1 4612/4885PDE8B 1125/4885 |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | POLB 912/4885L3MBTL1 2943/4885PDE8B 4353/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | POLB 1953/4885L3MBTL1 888/4885PDE8B 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.